Karyopharm Therapeutics (KPTI) Revenue (2012 - 2026)

Karyopharm Therapeutics (KPTI) has reported Revenue for 15 consecutive years, with $33.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue fell 11.86% year-over-year to $33.4 million; the trailing twelve-month figure through Jun 2026 stood at $149.5 million (up 8.9% YoY), and the FY2025 full-year result was $146.1 million, up 0.57% from the prior year.
• Revenue declined to $33.4 million in Q2 2026 per KPTI's latest filing, from $34.1 million in the prior quarter.
• Across five years, Revenue topped out at $47.7 million in Q1 2022 and bottomed at $30.0 million in Q1 2025.
• Historically, Revenue has averaged $36.9 million across 5 years, with a median of $36.1 million in 2022.
• The widest YoY moves for Revenue: up 104.94% in 2022, down 73.41% in 2022.
• Over 5 years, Revenue stood at $33.6 million in 2022, then increased by 0.5% to $33.7 million in 2023, then retreated by 9.5% to $30.5 million in 2024, then increased by 11.58% to $34.1 million in 2025, then declined by 1.9% to $33.4 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $33.4 million, $34.1 million, and $44.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.